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Background: The aging process involves a decline in immune functioning that renders elderly people more
vulnerable to disease. In residential programs for the aged, it is vital to diminish their risk of disease, promote their
independence, and augment their psychological well-being and quality of life.
Methods: We performed a randomized controlled study, evaluating the ability of a relaxation technique based
on Benson’s relaxation response to enhance psychological well-being and modulate the immune parameters of
elderly people living in a geriatric residence when compared to a waitlist control group. The study included a 2-week
intervention period and a 3-month follow-up period. The main outcome variables were psychological well-being and
quality of life, biomedical variables, immune changes from the pre-treatment to post-treatment and follow-up periods.
Results: Our findings reveal significant differences between the experimental and control groups in CD19, CD71, CD97,
CD134, and CD137 lymphocyte subpopulations at the end of treatment. Furthermore, there was a decrease in negative
affect, psychological discomfort, and symptom perception in the treatment group, which increased participants’ quality
of life scores at the three-month follow-up.
Conclusions: This study represents a first approach to the application of a passive relaxation technique in residential
programs for the elderly. The method appears to be effective in enhancing psychological well-being and modulating
immune activity in a group of elderly people. This relaxation technique could be considered an option for achieving
health benefits with a low cost for residential programs, but further studies using this technique in larger samples of
older people are needed to confirm the trends observed in the present study.
Trial registration: International Standard Randomised Controlled Trial Number Register ISRCTN85410212
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As we age, our immune response declines and there is a
greater susceptibility to disease due to a reduced ability to
fight infection or to accurately recognize foreign agents or
agents from the organism itself [1,2]. Various authors have
defended the working hypothesis that certain psycho-
logical interventions are able not only to augment an* Correspondence: areig@ua.es
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distribution, and reproduction in any mediumindividual’s psychological well-being, but also to im-
prove cell immune competence in humans [3-5]. Scien-
tific evidence, with respect to the utility and efficacy of
various psychological treatments and their beneficial
effects, is positive and solid [6-8], but the potential ben-
efits of psychological interventions on immune modula-
tion is much less noteworthy. The significant clinical
implications of the hypothetical relationship between
psychological treatment and immune modulation has
steered an ample number of empirical studies that aim
to study such relationship in various population samplestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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management was able to modify the immune response
and the course of the disease in patients with skin can-
cer [3,4,11]. A cognitive-behavioral therapy approach
yielded similar results by leading to increased produc-
tion of interleukins in patients with breast cancer during
the six months following psychological treatment [12].
However, contrasting results were found in women with
autoimmune disease for whom cognitive-behavioral
therapy changed emotional variables and enhanced
quality of life without altering immunological parame-
ters [13]. In recent years, interest in optimizing immune
function has led to investigating the efficacy of alterna-
tive techniques in modulating immune system activity
in healthy individuals, such as the practice of Hatha
yoga in normal adults [14], or of aerobic exercise in
elderly people [15]. A recent study showed that a de-
activation technique (i.e., mindfulness-based stress re-
duction) downregulated the expression of the NF-кB
pro-inflammatory gene in older adults [16]. Using a dif-
ferent approach, Kiecolt-Glaser et al. [5] reported that
training in a Jacobson-type muscle relaxation technique
(tensing and relaxing muscle groups) enhanced cellular
immune competence in the elderly.
Such optimization of immune function in older people
would have a great impact on their health status, decreasing
their susceptibility to disease and enhancing their quality of
life. Empirical evidence shows that our immune systems
weaken as we age and that factors such as genetics or
chronic stress could accelerate immune decline [17,18].
Although Jacobson’s relaxation technique effectively
enhanced cellular immune competence in older people
[5], the increased prevalence of muscle and joint disor-
ders in the elderly could hinder training and continued
practice of the technique. Consequently, we decided to
replace an active relaxation technique requiring muscle
engagement with an alternative, largely passive technique
that did not entail muscle relaxation and contraction.
Benson’s relaxation response [19] fit the requirements
and has proven efficacious in decreasing stress [20] and
anxiety, as well as in enhancing cognitive performance
in healthy aging [21]. In this study, we chose to label the
intervention as a “tranquilization technique” because
this term is well received by the elderly and it has a
calming psychological effect in the target population.
It is worth noting that older people are capable of
learning relaxation and meditation techniques adequately.
These methodologies have proven effective in decreasing
feelings of anxiety and hopelessness [22]. Some authors
suggest that relaxation, meditation, and guided imagery
(e.g., positive visualization) techniques are appropriate in
working with components of spiritual health that permit
a greater perception of well-being, a better connection
with the self, with others, and with a higher power [23].Therefore, the aim of this study was to test the effects of a
psychological program of geriatric intervention based on
the application of a passive relaxation technique, namely
Benson’s relaxation technique, on psychological well-being
and immune parameters in elderly people residing in a
nursing home. We hypothesized that the Benson’s tech-




Participants were 30 residents of a nursing home (79%
women), with a mean age of 83 years (SD = 4.97) and
ranging between 74 and 91 years. They all were briefed
on the details of the study and the intervention it
entailed by the physician of the institution. Those indi-
viduals interested in participating that fulfilled inclusion
criteria were admitted into the study.
The following were the inclusion criteria: (1) not to be
taking drugs with significant effects on endocrine or im-
mune function (e.g., corticosteroids or antimetabolites);
(2) not to have health problems directly related to im-
mune function (i.e., endocrine diseases, cancer, arthritis,
asthma, or infectious diseases); and (3) not have endured
an extremely negative life event within the year prior to
study participation. The exclusion criterion was that
there were indications of cognitive impairment. All par-
ticipants gave their informed consent to the study, which
had been approved by the Ethics Committee of the nurs-
ing home and of the University of Alicante, and followed
the guidelines of the Helsinki Declaration (AMM, 2008)
and the Good Clinical Practice Directive (Directive 2005/
28/EC) of the European Union.
Participants were randomly assigned to one of two
groups, by means of SPSS statistical software (version
20), with process of random numbers: the treatment
group (TG; n = 15) and a control group that was waitlisted
for intervention (CG; n = 15). The physician generated the
random allocation sequence, enrolled participants and
assigned participants to each groups. All participants
underwent medical and clinical tests, measures of psycho-
logical well-being and of health-related quality of life.
Functional assessment of the elderly was made by
means of the Katz Index of Activities of Daily Living
(ADL) [24], Spanish adaptation by Alvarez et al. [25].
Most participants were autonomous in their daily living
activities (i.e., bathing, dressing, toilet hygiene, functional
mobility, bowel and bladder control, and feeding). Ex-
ceptions to functional autonomy were three older indi-
viduals from the control group (B Index) and one from
the treatment group (C Index). There were no changes
in functional status throughout the intervention, except
for one member of the treatment group who suffered a
transient ischemic attack (TIA) and went from a Katz
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ities of Daily Living).
Measures
Psychological assessment
Psychological well-being and quality of life were assessed by
means of tests with adequate psychometric properties that
were culturally adapted to the sample. All instruments were
administered by appropriately trained personnel.
Satisfaction with Life Scale (SWLS) This scale consists
of five statements measuring degree of life satisfaction in
a Likert-scale format that goes from ‘strongly agrees’ to
‘strongly disagrees’ [26,27]. SWLS’ validity and reliability
are satisfactory [26]. Internal consistency of the scale, as
measured by Cronbach’s alpha, is greater than 0.80 in
the elderly population [28,29], and the average coeffi-
cient for different populations is 0.75 [30]. The SWLS
evaluates life satisfaction as current and past assess-
ments of the degree to which individuals have attained
their desired or planned life goals. Consequently, life sat-
isfaction as measured by this instrument provides a re-
flective and dispassionate evaluation of how well things
are going or have gone up to the present. We have used
the Spanish adaptation of Arce’s [31], which we have
successfully applied in previous research [27].
Affect Balance Scale (ABS) Bradburn’s Affect Balance
Scale [32] is aimed at determining a person’s psycho-
logical well-being at any given time. In the present study,
we used a Spanish adaptation for elderly people by Stock
et al. [33]. Psychometric characteristics of the scale are
adequate, with the authors reporting an internal consistency
of affect balance of 0.85, and a Cronbach’s alpha of 0.74
in a sample of Canadian elderly [34]. It appears, there-
fore, that the ABS is a sound measure of state affective
well-being. It is administered by an interviewer and in-
cludes 10 questions that have two possible answers: ‘yes’
(1) or ‘no’ (0). Five of the questions correspond to positive
affect, while the remaining five are related to negative
affective states. The affect balance score is calculated by
adding the positive items (A, C, E, G, I), dividing them
into the sum of the negative items (B, D, F, H, J), and add-
ing 5 points to the resulting number. The score ranges
from 0 to 10, from more negative to more positive affect.
The hedonic balance results from subtracting the sum of
the negative items from that of the positive items, with an
average value of zero and a range between -5 and +5. Posi-
tive scores correspond to a positive balance or euthymic
tone, whereas negative scores indicate a predominance of
dysthymic tone.
Nottingham Health Profile (NHP) The Nottingham
Health Profile [35] is a questionnaire that evaluateshealth-related quality of life. We used a Spanish adapta-
tion for elderly people by Richart-Martinez et al. [29]. It
contains two sections, with the first one measuring the
perceived health status in terms of a series of regular
problems or complaints that people have in their daily
lives, while the second section focuses on activities that
can be affected by the health status of the individual.
The first section includes 38 questions pertaining to six
areas: Energy, Pain, Emotional Reactions, Sleep, Social
Isolation, and Physical Mobility. Interviewees answer
‘yes’ or ‘no’ to each question. The second section con-
sists of ‘yes’ or ‘no’ statements about seven areas of life
that are most affected by health status.
This instrument was selected because it is one of the
most frequently used with geriatric populations, is easy
to understand, and is readily accepted by elderly people
[29,35,36]. Furthermore, it has acceptable psychometric
properties [29,36], with test-retest reliability over 0.70
for each of the scales in the first portion of the question-
naire, and between 0.44-0.86 for items in the second
portion of the profile, in addition to good content and
criterion validity [29,35].
Benson’s Symptom List Benson suggested that prac-
ticing the relaxation technique had beneficial effects on
a series of symptoms: anxiety and hyperventilation; in-
somnia; headaches; back pain; and thoracic pain [37].
Global scores of the Benson Symptom List range from 1
to 5 points.
Assessment of biomedical variables
The following measures were taken at the beginning of
treatment, 15 days following the end of the treatment
sessions, and at follow-up, three months after finishing
treatment:
a) Clinical history from the start of the treatment
program and for the following 6 months. The
presence of multiple pathologies, which characterize
geriatric populations, intercurrent diseases, and
pharmacological treatments were registered
throughout the duration of the study.
b) Functional assessment by means of Katz Index of
ADL [25].
c) Physical parameters: Weight, height, Body Mass
Index (BMI), blood pressure, and heart rate.
d) Hematological parameters: red and white blood cells
counts, and blood differential (CBC), hemoglobin,
hematocryte, mean corpuscular volume (MCV),
platelets, and erythrocyte sedimentation rate (ESR).
e) Blood biochemistry measures: Glucose, creatinine,
urea, uric acid, total cholesterol, HDL and LDL
cholesterol, triglycerids, AST, ALT, GGT, total
proteins, and serum albumin.
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in the laboratory of the Service of Clinical Analysis of the
San Juan Clinical University Hospital in Alicante (Spain).
Blood samples were collected in the morning following a
12-hour fast. Samples were processed immediately. At that
same time, blood samples collected to assess immune
function were refrigerated and sent to the laboratory
within 6 hours after collection. Research staff taking mea-
surements and processing samples were blinded to the
group condition (treatment or waitlist group).
Immunological assessment
Immune cells carry out some of their functions by
means of cell-to-cell contact and via membrane recep-
tors or antigens that are expressed at the cellular surface.
Some molecules appear at various stages of cell differen-
tiation or activation. In the present study, we recorded
the following molecules: CD4, CD8, CD19, CD56, CD71,
CD97, CD134, and CD173.
Phenotypic analysis of the various cell populations
was carried out by immunofluorescence by means of
flow cytometry with double or triple labeling. This tech-
nique constitutes a useful tool for cell identification and
characterization. Following intravenous peripheral blood
collection, 50 μl of blood were incubated for 10 minutes
with 3 μl of the following combinations of monoclonal
antibodies (Pharmigen):
– CD4-PE + CD8-FITC + CD19-Cy5
– CD8-FITC + CD56-PE
– CD71-FITC + CD97-PE
– CD134-FITC + CDw137-PE
Afterwards, 1 mL of a hematolysis solution (Quicklysis,
Cytognos) was added and the blood solution was kept in
the dark for 5 minutes, after which time 10,000 cells were
subjected to cytometric analysis.
Immunofluorescence analysis was carried out by means
of a Vantage (Becton Dickinson) FACS flow cytometer,
equipped with an argon laser (488 nm) that excites the
FITC, PE, and Cy5 fluorchromes, emitting at 520, 575,
and 667 nm, respectively.
Psycho-gerontology intervention
Psychological treatment was conducted by an expert
psychologist in the practice of this technique. It con-
sisted of empirical training in the “relaxation response”
technique designed by Benson [19], which we named the
“tranquilization technique”. The technique is extremely
effective in controlling and decreasing stress levels and
the associated tension, as well as in bringing about a
sense of personal well-being. The following requirements
are of paramount importance: (a) a quiet environment;
(b) a word or phrase that is repeated and on which theperson focuses attention; (c) a passive attitude; and (d) a
comfortable posture.
This relaxation technique consists of engaging in re-
peated resting periods in which the mind is free from pre-
occupations and the body is liberated of all tension. This
state is reached by focusing on a special object, usually a
word o phrase. In this study, the word “dos” (“two” in
English) was used to achieve the relaxation response.
Procedure
The study was conducted in a relaxing and quiet room
of a public nursing home in Alicante, Spain. Chairs were
mobile and comfortable.
On the first day, the researchers carrying out the study
introduced themselves and the task to be accomplished.
They explained the aims of the relaxation technique (i.e.,
to enhance their physical and psychological well-being,
and to achieve a greater personal serenity), the reason
for the questions they would be asked immediately (pre-
test), as well as at the end of the relaxation training, and
three months after the study was finished. Researchers
also explained the purpose of the various analyses and
clinical tests, and the need to have them repeated.
Several questionnaires and tests (see 2.2. Psychological
assessment) were individually administered on the first
and last days of treatment. On those occasions, partici-
pants were also asked about the symptoms and health
problems that Benson claimed could be modified by
practicing his relaxation technique: anxiety and hyper-
ventilation, insomnia, headaches, back pain, thoracic
pain, hypertension, heart rate and heart problems, sec-
ondary symptoms of cancer, and cholesterol levels.
Hour-long group sessions were conducted daily, from
Monday through Friday, for a total of 10 days in a span
of two weeks. At the end of each group session, partici-
pants were encouraged to practice the technique two or
three more times within the 24 hours leading to the next
session. Training sessions were scheduled at noon, a
time that was several hours away from breakfast and the
main meal of the day (in Spain).
Assessments were repeated at the end of treatment
and three months later. On this last evaluation, the
treatment group was asked for a subjective appraisal of
the relaxation experience and their practice routine over
the three months leading to the follow up.
The control group (i.e., the waitlist group) was assessed
in the same fashion as the treatment group and following
the same sequence (right before the beginning of the treat-
ment, at the end, and three months later).
Statistical analysis
Type of treatment (relaxation technique vs. waitlist) di-
vided participants into two groups: treatment and control.
All other variables were considered repeated measures:
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and quality of life, clinical and biomedical tests, and im-
munological tests.
All statistical analyses were conducted by means of
SPSS statistical software (version 20). The non-parametric
Mann–Whitney U test for independent samples was used
to test for group effects on the various dependent mea-
sures at the three assessment times (A = before treatment;
B = immediately after treatment; C = three months after
treatment).
Within-subject pre- and post-treatment effects on the
dependent measures compared pre-treatment to post-
treatment (A vs. B), and pre-treatment to the three-
month follow-up (A vs. C). It was performed by means
of Wilcoxon’s T test, a non-parametric test for related
samples.
Results
The nursing home had 100 residents, and 70 were ex-
cluded for not meeting inclusion criteria or because they
declined participation in the study. Thirty participants
were randomly assigned to each group. The treatment
group consisted of 15 people, but just 11 participants
finished the intervention, because two participants never
initiated the treatment after randomization, one partici-
pant had to be hospitalized due to a diabetic nephropa-
thy that caused his death; a second one suffered a TIA
that resulted in hemiplegia and aphasia. The waitlist
group, consisted of 15 people in the beginning, but one
participant was not evaluated at the follow-up phase due
to a TIA with hemiplegia and aphasia.
Figure 1 includes a CONSORT flowchart, detailing the
recruitment procedure, group assignment, and reasons
for attrition for each group of participants.
Below, we report the most significant results, grouped
into psychological, clinical-medical, and immunological
variables. Each subheading includes data for both groups
(treatment vs. waitlist control) and three assessments
(before treatment, immediately after treatment, and three-
month follow up).
Psychological assessment
Table 1 includes results of psychological tests for both
groups. Pre-treatment (time A) testing shows that psy-
chological well-being was reasonably good for both
groups, taking into account that all participants were
elderly and residing in a nursing home. Results indicate
that participants had levels of psychological well-being
(i.e., mood and life satisfaction) comparable to those of
elderly people in a community setting.
Statistical analyses also demonstrated that there were
no significant differences between groups prior to relax-
ation training. The single exception to this pattern was
the Emotional Reactions of the Nottingham HealthProfile, whereby scores were higher for the treatment
group. These differences, however, disappeared over the
course of the following evaluations, with the treatment
group reporting less psychological distress after treat-
ment (p = 0.02), in comparison with the control group,
whereby no differences are observed.
Similarly, negative affect scores of the Affect Balance
Scale decreased after treatment for the treatment group,
with results being marginally significant (p = 0.05). The
relaxation technique had a positive impact on self-report
symptom measures (p = 0.04), with the treatment group
reporting fewer symptoms after treatment. All other psy-
chological variables remained unaffected by the inter-
vention at the various assessment times.
The waitlist control group did not show any changes
in any of the measures of psychological well-being or
quality of life at any of the assessment points.
Results indicate a trend toward improvement of
health-related quality of life scores following treatment
(NHP total score, p = 0.05). This trend suggests that
health-related quality of life continues to improve over
time after relaxation training (A = 18.15, B = 16.62, and
C = 15.27; whereby lower scores represent better out-
comes), although the trend does not reach statistical sig-
nificance. Figure 2 includes weighted averages for each
of the NHP scales at each of the three assessment times,
showing how all scale scores decreased over time, with
the exception of the scale measuring sleep problems.
Biomedical and clinical measures
Description of clinical variables for all participants
Table 2 includes all prevalent pathologies in the treat-
ment and waitlist control groups.
Medical and laboratory measures
Table 3 presents all clinical-biomedical results for both
groups at the three assessment times.
BMI measures led to a diagnosis of obesity in 6 mem-
bers of the treatment group and 4 members of the
control group (i.e., BMI > 30). Six individuals from the
treatment group and 8 controls showed systolic blood
pressures greater than 140 mmHg. No participants had
diastolic blood pressure over 90 mmHg.
There were no statistical differences between groups
in terms of clinical, hematological, and biochemical mea-
sures at the beginning of the intervention. The only ex-
ception was a greater proportion of polymorphonuclear
leukocytes in the treatment group than in the control
group (56.4% vs. 48.9%, p < 0.005), a difference that is
also present at the end of treatment but disappears at
follow-up.
After treatment, there were significant differences be-
tween groups in the proportion of lymphocytes (TG:
30.66%; CG: 36.99%; p < 0.05), although these differences
Figure 1 CONSORT flowchart of participants retained at each phase of the trial.
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appear at follow-up. Three months after treatment, the
control group shows a greater proportion of basophils
(0.69%) than the treatment group (0.48%) (p < 0.05). Also
at follow-up, the treatment group showed significantly
increased levels of hemoglobin (p < 0.02), creatinine (p <
0.04), urea (p < 0.02), and total protein (p < 0.02), as well
as decreased levels of the mean corpuscular volume
(MCV) (p < 0.01) and platelets (p < 0.03).
At follow-up, however, the control group also evidenced
significant increases in the level of creatinine (p < 0.001),
HDL cholesterol (p < 0.001), GGT (p < 0.01) and total pro-
tein (p < 0.001).
Immunological testing
Table 4 includes results of the immunological testing for
each group at the three assessment times.
Although there were no significant differences be-
tween groups in any of the immunological values prior
to treatment, differences in CD19 (Mann–Whitney U
test; z = −1.97, p = 0.04), CD71 (Mann–Whitney U test;
z =−1.98, p= 0.04), CD97 (Mann–Whitney U test; z =−2.46,
p = 0.01), CD134 (Mann–Whitney U test; z = −2.26,
p = 0.02), and CD137 (Mann–Whitney U test; z = −2.25,
p = 0.02), became significant after treatment, only to
disappear at the three-month follow-up assessment.In terms of within-subject effects, at the post-treatment
assessment (B) the treatment group showed a significant
decrease in CD19+ B lymphocytes (p = 0.015), as well as
in CD134 lymphocytes (p = 0.003), whereas CD71 and
CD97 markers were significantly increased (p = 0.001 and
p = 0.002, respectively). Significant changes in CD19 (p =
0.05), CD71 (p = 0.01), and CD97 (p < 0.001) were main-
tained over the three months following the treatment,
while CD137 (p = 0.03) values were significantly higher at
follow-up.
For the control group, the values of CD71 and CD97
were significantly increased from the pre-treatment to
the post-treatment assessment (ps < 0.001), and remained
unchanged for the three-month follow-up. In contrast,
CD134 values were significantly decreased between pre-
and post-treatment assessments (p < 0.001).
Discussion
In Spain, this is the first time in which a relaxation tech-
nique is used in the treatment of elderly residents of a
nursing home and in which psychological, biomedical,
and immunological measures are obtained. Our aim was
to use this relaxation method as a psycho-gerontological
intervention and assess its capacity for enhancing psy-
chological well-being and immune parameters in aging
adults. We understand that a “psycho-gerontological
Table 1 Means (M) and standard deviations (SD) of psychological measures for participants of both groups
Variable Group A M± SD Mann-Whitney
U
B M ± SD Mann-Whitney
U
C M ± SD Mann-Whitney
U
Wilcoxon’s
T A vs. B
Wilcoxon’s
T A vs. C
z p z p z p z p z p
SWLS TG 16.46 ± 5.24 −0.39 0.69 17.92 ± 3.71 −0.34 0.72 16.91 ± 4.74 −1.07 0.28 −1.53 0.12 0.00 1.00
CG 17.80 ± 3.34 17.13 ± 5.17 18.93 ± 3.84 −0.51 0.60 −0.94 0.34
Positive Affect TG 2.85 ± 1.34 −1.85 0.06 2.54 ± 0.97 −0.19 0.84 2.73 ± 1.10 −0.62 0.53 −0.78 0.43 −0.99 0.31
CG 2.00 ± 1.11 2.40 ± 1.24 2.40 ± 1.24 −1.22 0.22 −1.23 0.21
Negative Affect TG 3.15 ± 1.21 −1.59 0.11 2.38 ± 0.96 −0.55 0.58 3.00 ± 1.34 −0.80 0.42 −1.89 0.05 −0.36 0.71
CG 2.36 ± 1.34 2.60 ± 1.12 2.60 ± 1.24 −0.18 0.85 −0.36 0.71
Affect: TG −0.31 ± 1.60 −0.47 0.63 0.15 ± 0.69 −0.83 0.40 −0.27 ± 0.90 −0.29 0.76 −0.99 0.32 −0.66 0.50
Hedonic balance CG −0.36 ± 1.39 −0.20 ± 1.21 −0.20 ± 1.08 −0.85 0.39 −0.55 0.58
Affect: TG 4.69 ± 1.60 −0.47 0.63 5.15 ± 0.69 −0.83 0.40 4.73 ± 0.90 −0.29 0.76 −0.99 0.32 −0.66 0.50
Standardized ABS CG 4.64 ± 1.39 4.80 ± 1.21 4.80 ± 1.08 −0.08 0.39 −0.55 0.58
NHP
Energy TG 1.77 ± 1.17 −0.40 0.68 2.00 ± 1.15 −0.92 0.35 1.36 ± 1.43 −0.51 0.60 −0.87 0.38 −0.96 0.33
CG 1.53 ± 1.30 1.60 ± 1.12 1.53 ± 1.19 −0.44 0.65 0.00 1.00
Pain TG 3.62 ± 2.90 −1.00 0.31 3.46 ± 3.10 −0.67 0.49 2.91 ± 2.51 −0.13 0.89 −0.10 0.91 −1.02 0.30
CG 2.60 ± 2.64 2.87 ± 3.27 3.00 ± 3.16 −0.27 0.78 −0.49 0.62
Emotional TG 4.85 ± 1.68 −2.01 0.04 3.54 ± 1.85 −0.02 0.98 3.64 ± 2.98 −0.18 0.85 −2.22 0.02 −1.79 0.07
Reactions CG 3.53 ± 1.85 3.73 ± 2.31 3.13 ± 1.88 −0.14 0.88 −0.71 0.47
Sleep TG 2.54 ± 1.56 −0.46 0.63 2.46 ± 1.61 −0.12 0.90 3.09 ± 1.30 −1.36 0.17 −0.58 0.56 −1.41 0.15
CG 2.27 ± 1.67 2.53 ± 1.85 2.13 ± 1.92 −1.15 0.24 −0.43 0.66
Social TG 1.23 ± 1.24 −0.26 0.79 0.85 ± 0.99 −0.53 0.59 0.91 ± 1.22 −0.08 0.93 −0.50 0.13 −1.29 0.19
Isolation CG 1.33 ± 1.23 1.27 ± 1.49 1.13 ± 1.46 −0.06 0.95 −0.88 0.37
Physical TG 4.15 ± 2.12 −0.81 0.41 4.31 ± 2.81 −1.06 0.28 3.36 ± 2.46 −0.07 0.93 −0.41 0.68 −1.93 0.05
Mobility CG 3.67 ± 2.29 3.13 ± 2.67 3.33 ± 2.19 −1.24 0.21 −0.81 0.41
NHP Total TG 18.15 ± 7.49 −1.08 0.27 16.62 ± 8.33 −0.43 0.66 15.27 ± 7.88 −0.39 0.69 −1.02 0.30 −1.89 0.05
CG 14.93 ± 6.93 15.13 ± 9.78 14.27 ± 9.07 −0.11 0.90 −0.66 0.50
Benson’s Five TG 2.85 ± 1.28 −1.18 0.23 1.83 ± 1.03 −0.40 0.68 2.36 ± 1.43 −0.79 0.42 −2.04 0.04 −0.95 0.34
Symptoms CG 2.27 ± 1.53 2.00 ± 1.20 1.87 ± 1.51 −0.81 0.41 −1.11 0.26
Note: Between-group comparisons (Mann–Whitney U test) at three assessment times; and within-subject analyses (Wilcoxon’s T) comparing pre-treatment
assessment (A) with post-treatment assessment (B) and follow-up assessment (C). TG: Treatment Group; CG: Waitlist Control Group; M: Mean (SD: Standard
Deviation); ABS: Affect Balance Scale; SWLS: Satisfaction with Life Scale; NHP: Nottingham Health Profile.
















Figure 2 Weighted scores for the treatment group: Nottingham Health Profile at the three assessment times. A: pre-treatment
assessment; B: post-treatment assessment; C: three-month follow-up assessment. E: Energy; P: Pain; ER: Emotional Reactions; S: Sleep; SI: Social
Isolation; PM: Physical Mobility.
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Table 2 Prevalence of medical pathologies
Treatment group Control group
Hypertension 8 8
Mood disorders 7 4
Sensory disorders 5 -
Musculoskeletal pathologies 4 4
Diabetes 3 3
Heart failure 2 2
COPD 1 -
Benign prostatic hyperplasia 1 -
Parkinson’s disease 1 -
Acute myocardial infarction - 1
Pacemaker - 2
Chronic renal failure - 2
Previous stroke - 1
Adrenal/thyroid insufficiency - 1
Note: COPD: Chronic Obstructive Pulmonary Disease.
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http://www.biomedcentral.com/1472-6882/14/311intervention” can be construed as a procedure designed
to improve the physical and psychological well-being of
elderly people by affecting changes at the emotional,
cognitive, or behavioral levels. Prior studies have sought
to alleviate the immune dysregulation brought about by
stress by means of different relaxation techniques (e.g.,
relaxation or calming responses, progressive muscle relax-
ation, biofeedback-assisted relaxation) [38-41]. Mahbub-
E-Sobhani et al. [42], in their review of immune modula-
tion in response to stress and relaxation, concluded that
there is a variety of stressors that have a negative impact
on immune function (for instance, by secreting glyco-
corticoids), but that approaches akin to relaxation tech-
niques could help maintain homeostasis by secreting
β-endorphins that trigger an increase in NK cells and,
thus, enhance immunity.
Research has shown that immune function is affected
both by stress and by normal aging, and these two fac-
tors interact, producing a decline in immune activity
[18,43]. The sample in our study was composed of eld-
erly people without obvious stress problems (except for
those associated with their health) and without high
levels of psychological distress. Nevertheless, relaxation
training improved their quality of life and modulated
some of their immune parameters. At the psychological
level, the relaxation technique produced positive effects
in that there was a decline in negative affect, degree of
psychological distress, and perception of symptomatol-
ogy with respect to baseline levels at the beginning of
the study. Furthermore, the treatment group showed
gains in quality of life at the three-month follow-up.
Our results suggest that the relaxation technique is
capable of significantly decreasing psychological distress
in a group of elderly people. Research has examinedemotional distress and its influence on three important
systems: the nervous system, the endocrine system, and
the immune system; three systems that interact among
themselves and, thus, can disrupt one another [44]. If we
take into account that the “Emotion Reactions” scale of
the Nottingham Health Profile measures severe psycho-
logical distress, and that only the treatment group
showed lower scores at the post-treatment assessment,
we can conclude that treatment results were clearly
beneficial. The NHP measures chronic psychological dis-
tress, and not just situational distress. Although the re-
laxation technique did not enhance positive affect, it was
effective in diminishing negative affect, which had been
previously linked to disruptions of immune system func-
tion [9]. Creswell et al. [16] obtained changes in negative
feelings, especially feelings of isolation, by implementing
an 8-week Mindfulness-Based Stress Reduction (MBSR)
program. In addition to significantly decreasing feelings
of loneliness in healthy older adults, the program led to
the down regulation of pro-inflammatory NF-κB-related
gene expression in circulating leukocytes. Creswell and
his collaborators claim that feelings of loneliness dimin-
ish because of a change in the perception of social threat
that develops by MBSR training [16]. Moreover, they
suggest that changes in pro-inflammatory NF-κB-related
gene expression are due to the mind-body connection
that is generated by the MBSR technique, thus acting on
the stress-mediating axes responsible for the expression
of the gene. Similar results have been obtained with a
group of breast-cancer patients following a psychological
intervention [45]. Decreases in feelings of loneliness [16]
and those found here in terms of negative affect, are in
agreement with the proposal by Quinceno and Vinaccia
[23] that, by using relaxation and calming techniques,
individuals perceive that there is greater social support,
experience feelings of well-being and life satisfaction, ob-
tain better self-awareness and a greater connection with
others and with a higher power.
The existence of immune-neuroendocrine communi-
cations is widely accepted [46-48]. Those factors that
cause changes or alterations in the endocrine system
have negative effects on the immune system such as low
lymphocyte mitogen response, decreased NK activity, al-
tered T cell populations, or deregulation of cytokines
and their receptors [49,50]. However, the mechanism by
which neuroendocrine alterations affect the immune sys-
tem is unclear [51].
Several parameters have been used to analyze the
immune-neuroendocrine relations, in both nonspecific
and specific immunity and, within this, both cell and
humoral response [52-55].
Our results show significant group differences in vari-
ous lymphocyte subpopulations after the intervention
that disappeared three months later. This could be due
Table 3 Clinical measures of both groups at three assessment times
Variable Group A M ± SD Mann-Whitney U B M ± SD Mann-Whitney U C M ± SD Mann-Whitney U Wilcoxon’s T A versus B Wilcoxon’s T A versus C
z p z p z p z p z p
SBP (mmHg) TG 143.08 ± 21.65 0.00 1.00 138.08 ± 19.53 −0.74 0.45 135.00 ± 19.16 −0.66 0.51 −0.90 0.36 −1.63 0.10
CG 141.67 ± 19.88 144.44 ± 20.53 141.67 ± 17.22 −0.77 0.43 −0.63 0.52
DBP (mmHg) TG 75.77 ± 12.72 −0.37 0.70 74.62 ± 9.00 −0.27 0.78 67.50 ± 9.57 −1.26 0.20 −0.27 0.78 −1.13 0.25
CG 72.33 ± 10.33 75.56 ± 9.82 75.00 ± 8.37 −0.43 0.66 −0.13 0.89
HR (bpm) TG 79.08 ± 12.12 −0.95 0.34 80.09 ± 14.02 −1.07 0.28 - - - −0.10 0.91 - -
CG 73.27 ± 8.45 73.00 ± 7.35 - −0.35 0.72 - -
Leukocytes/mm3 TG 6646.15 ± 1145.73 −0.29 0.77 6584.62 ± 1003.20 −1.23 0.21 6180.00 ± 1139.98 −0.78 0.43 −0.52 0.60 −1.63 0.10
CG 6450.00 ± 1399.31 6192.31 ± 1515.18 6861.54 ± 1526.18 −0.35 0.72 −0.39 0.69
Segmented (%) TG 56.74 ± 7.70 −0.34 0.01 56.38 ± 7.41 −2.30 0.02 59.44 ± 7.77 −1.67 0.09 −0.17 0.86 −1.07 0.28
CG 47.55 ± 11.31 48.93 ± 8.56 51.89 ± 10.34 −1.05 0.28 −1.29 0.19
Limphocytes (%) TG 30.55 ± 7.90 −1.82 0.06 30.66 ± 6.77 −2.38 0.01 28.92 ± 6.80 −1.36 0.17 −0.14 0.88 −0.81 0.41
CG 38.02 ± 12.50 36.99 ± 7.16 35.48 ± 10.73 −0.15 0.87 −0.31 0.75
Monocytes (%) TG 8.63 ± 1.63 −0.87 0.38 8.72 ± 1.92 −0.61 0.53 9.12 ± 2.02 −0.50 0.62 0.00 1.00 −1.71 0.08
CG 9.67 ± 2.63 9.07 ± 1.99 8.72 ± 2.34 −0.27 0.78 −1.29 0.19
Eosinophils (%) TG 3.56 ± 1.82 −0.72 0.46 3.64 ± 2.00 −0.64 0.52 3.64 ± 2.24 −0.59 0.55 0.00 1.00 −0.25 0.79
CG 4.15 ± 2.60 4.28 ± 2.61 3.96 ± 1.99 −0.23 0.81 −1.11 0.26
Basophils (%) TG 0.50 ± 0.21 −0.71 0.47 0.73 ± 0.58 −0.31 0.75 0.48 ± 0.12 −2.01 0.04 −1.07 0.28 −0.81 0.41
CG 0.58 ± 0.33 0.70 ± 0.43 0.69 ± 0.33 −0.27 0.78 −1.54 0.12
Red blood (cells/mm3) TG 4.42 ± 0.33 −1.05 0.29 4.49 ± 0.37 −1.13 0.25 4.53 ± 0.38 −1.34 0.17 −0.80 0.42 −1.68 0.09
CG 4.30 ± 0.39 4.36 ± 0.49 4.31 ± 0.35 −1.29 0.19 −0.39 0.69
Hemoglobin (g/dl) TG 13.47 ± 1.18 −1.43 0.15 13.61 ± 1.31 −1.07 0.28 13.90 ± 1.20 −1.40 0.16 −0.87 0.38 −2.19 0.02
CG 12.86 ± 1.28 13.04 ± 1.67 13.08 ± 1.17 −0.93 0.35 −1.33 0.18
Hematocrit (%) TG 41.66 ± 3.57 −1.67 0.09 41.75 ± 3.83 −1.18 0.23 41.52 ± 3.81 −0.59 0.55 −0.24 0.80 −0.15 0.87
CG 39.35 ± 3.71 39.82 ± 4.31 40.57 ± 3.42 −0.90 0.36 −1.41 0.15
MCV (fl) TG 94.23 ± 4.53 −1.62 0.10 93.40 ± 4.61 −1.10 0.27 92.14 ± 4.41 −1.18 0.23 −2.62 0.00 −2.49 0.01
CG 91.45 ± 5.27 91.80 ± 5.14 94.29 ± 6.01 −0.49 0.62 −1.86 0.06
Platelets/mm3 TG 232.38 ± 49.53 −1.57 0.11 234.77 ± 55.25 −1.71 0.08 196.70 ± 37.78 −0.12 0.90 −0.38 0.70 −2.14 0.03
CG 197.57 ± 41.64 197.00 ± 38.20 203.66 ± 62.30 −0.66 0.50 −0.15 0.87
ESR (mm/h) TG 40.25 ± 21.93 −0.69 0.48 44.55 ± 31.70 0.22 0.82 29.14 ± 18.84 −0.76 0.44 −0.77 0.44 −0.94 0.34
CG 35.36 ± 27.54 45.29 ± 23.96 41.50 ± 29.78 −0.63 0.52 −0.44 0.65
Glycemia (mg/dl) TG 108.08 ± 23.46 −2.21 0.22 108.82 ± 31.59 −0.60 0.54 102.0 ± 29.21 −1.05 0.29 −0.89 0.37 −0.25 0.79
























Table 3 Clinical measures of both groups at three assessment times (Continued)
Creatinine (mg/dl) TG 0.92 ± 0.18 −0.87 0.38 0.92 ± 0.22 −1.45 0.14 0.97 ± 0.19 −1.68 0.09 −0.71 0.47 −2.00 0.04
CG 1.01 ± 0.30 0.99 ± 0.18 1.13 ± 0.36 −1.45 0.14 −2.74 0.00
Urea (mg/dl) TG 34.23 ± 9.75 −1.91 0.05 38.27 ± 6.39 −1.62 0.10 41.09 ± 8.70 −0.87 0.38 −2.32 0.02 −2.18 0.02
CG 6.87 ± 20.27 46.31 ± 12.43 51.46 ± 20.53 −0.17 0.86 −1.18 0.23
Uric Acid (mg/dl) TG 4.58 ± 1.23 −1.45 0.14 4.50 ± 1.55 −1.59 0.11 4.75 ± 1.41 −1.30 0.19 −1.11 0.26 −0.89 0.37
CG 5.58 ± 1.81 5.52 ± 1.40 5.57 ± 1.50 −0.24 0.80 −0.17 0.86
Cholesterol (mg/dl) TG 196.46 ± 29.01 −0.53 0.59 190.00 ± 35.79 −1.04 0.29 215.64 ± 40.38 −0.98 0.32 −0.22 0.82 −1.86 0.06
CG 202.93 ± 46.63 210.54 ± 47.76 202.15 ± 30.02 −1.51 0.13 −0.35 0.72
HDL Cholesterol TG 51.50 ± 12.66 −0.29 0.77 52.03 ± 13.29 −0.23 0.81 55.19 ± 13.74 −0.46 0.64 −0.10 0.91 −1.47 0.13
(mg/dl) CG 53.00 ± 11.67 50.95 ± 9.66 56.35 ± 13.10 −1.12 0.26 −2.66 0.00
Triglycerides (mg/dl) TG 135.46 ± 70.04 −0.73 0.46 128.18 ± 68.05 −0.40 0.68 137.36 ± 92.12 −0.20 0.83 −1.24 0.21 −0.35 0.72
CG 126.20 ± 75.86 146.62 ± 95.11 104.00 ± 27.91 −0.98 0.32 −0.07 0.93
LDL Cholesterol TG 117.86 ± 29.38 −0.68 0.49 112.32 ± 31.70 −1.04 0.29 131.47 ± 33.46 −0.97 0.33 0.00 1.00 −1.48 0.13
(mg/dl) CG 130.77 ± 28.01 128.33 ± 36.95 125.32 ± 25.37 −0.84 0.40 −0.65 0.51
AST (U/L) TG 22.37 ± 5.08 −0.76 0.44 19.88 ± 5.97 −0.66 0.50 26.90 ± 15.21 −1.36 0.17 −2.40 0.01 −0.44 0.65
CG 21.49 ± 6.91 21.59 ± 5.90 19.99 ± 7.71 −0.10 0.91 −0.45 0.65
ALT (U/L) TG 18.41 ± 4.85 −0.96 0.33 15.72 ± 5.01 −0.49 0.62 14.00 ± 5.50 −0.78 0.43 −2.84 0.04 −1.95 0.05
CG 18.73 ± 12.10 18.90 ± 11.43 17.73 ± 9.72 −0.59 0.55 −1.01 0.31
GGT (U/L) TG 19.93 ± 6.88 −0.58 0.56 18.88 ± 3.90 −0.63 0.52 19.23 ± 5.05 −1.16 0.24 −1.29 0.19 −0.88 0.37
CG 32.14 ± 30.03 20.29 ± 14.50 39.80 ± 39.82 −1.02 0.30 −2.59 0.01
Total proteins (gr/dl) TG 6.90 ± 0.48 −1.24 0.21 6.90 ± 0.42 −0.06 0.94 7.31 ± 0.42 −0.03 0.97 −1.13 0.25 −2.19 0.02
CG 6.71 ± 0.48 6.88 ± 0.38 7.26 ± 0.34 −1.49 0.13 −2.90 0.00
Albumin (gr/dl) TG 3.93 ± 0.32 −0.09 0.92 3.87 ± 0.18 −0.49 0.62 4.02 ± 0.18 −0.76 0.44 −0.17 0.85 −0.05 0.95
CG 3.95 ± 0.30 3.82 ± 0.34 4.10 ± 0.26 −0.80 0.42 −1.33 0.18
Note: Between-group (Mann–Whitney U test) and within-subject (Wilcoxon’s T test) effects for clinical values at three assessment times. TG: Treatment Group; CG: Waitlist Control Group; M: Mean ± SD: Standard
Deviation); SBP: Systolic Blood Pressure; DBP: Dyastolic Blood Pressure; HR: Heart Rate; MCV: Mean Corpuscular Volume; ESR: Erythrocyte Sedimentation Rate; AST: Aspartate aminotransferase; ALT: Alanine
























Table 4 Immunological measures of both groups at three assessment times
Variable Group A M± SD Mann–Whitney
U
B M± SD Mann–Whitney
U
C M± SD Mann–Whitney
U
Wilcoxon’s
T A vs. B
Wilcoxon’s
T A vs. C
z p z p z p z p z p
CD19 TG 6.60 ± 2.53 −0.23 0.81 4.86 ± 1.33 −1.97 0.04 4.72 ± 3.60 −0.80 0.41 −2.43 0.01 −1.95 0.05
CG 6.85 ± 1.74 6.75 ± 3.08 5.25 ± 2.49 −0.17 0.86 −1.76 0.07
CD4 TG 41.43 ± 11.40 −0.48 0.62 43.83 ± 6.67 −0.66 0.50 51.90 ± 24.62 −0.06 0.95 −0.66 0.50 −1.51 0.13
CG 40.36 ± 10.74 45.51 ± 9.15 47.83 ± 10.22 −1.08 0.27 −1.25 0.20
CD8 TG 18.59 ± 6.11 −0.64 0.51 21.13 ± 4.42 −1.28 0.20 22.27 ± 14.24 −0.61 0.53 −1.01 0.31 −0.66 0.50
CG 18.54 ± 3.51 19.01 ± 6.65 23.08 ± 12.81 0.00 1.00 −0.78 0.43
CD56 TG 20.52 ± 7.72 −0.46 0.64 22.93 ± 5.21 −0.05 0.95 20.18 ± 13.38 −1.05 0.29 −0.87 0.38 −0.53 0.59
CG 18.58 ± 6.10 24.16 ± 10.93 23.00 ± 7.43 −1.74 0.08 −1.64 0.09
CD71 TG 0.53 ± 0.24 −0.09 0.92 3.52 ± 1.74 −1.98 0.04 2.00 ± 1.54 −1.45 0.14 −3.18 0.00 −2.94 0.00
CG 0.54 ± 0.30 2.23 ± 1.12 2.25 ± 0.75 −3.11 0.00 −3.06 0.00
CD97 TG 0.77 ± 0.78 −0.58 0.55 2.90 ± 1.79 −2.46 0.01 2.63 ± 1.56 −0.51 0.60 −3.11 0.00 −2.58 0.01
CG 0.69 ± 0.57 5.34 ± 2.96 2.33 ± 1.30 −3.18 0.00 −2.59 0.01
CD134 TG 1.03 ± 0.49 −0.97 0.32 0.28 ± 0.22 −2.26 0.02 1.49 ± 0.93 −0.33 0.73 −2.97 0.00 −0.48 0.62
CG 1.26 ± 0.44 0.63 ± 0.44 2.06 ± 2.48 −2.83 0.00 −0.40 0.68
CD137 TG 0.14 ± 0.07 −1.09 0.27 0.09 ± 0.07 −2.25 0.02 0.63 ± 0.70 −0.25 0.80 −1.73 0.08 −2.14 0.03
CG 0.18 ± 0.10 0.17 ± 0.09 1.19 ± 0.00 0.00 1.00 −1.53 0.12
Note: Between-subject (Mann–Whitney U test) and within-subject (Wilcoxon’s T test) effects for immunological values at three assessment times. Means are
expressed as percentages of total number of lymphoid cells. TG: Treatment Group; CG: Waitlist Control Group; M: Mean (SD: Standard Deviation); A: pre-treatment
assessment; B: post-treatment assessment; C: three-month follow-up assessment.
Bold text: p < 0.05.
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that this type of treatment shows a greater effectiveness
when employed by people under stress associated with
immune disorders [56,57]. However, older people do not
always present relevant conditions of acute stress. In
fact, stress levels in old age are often well below those
found during other phases of the lifespan [58,59]. Miller
and Cohen [10] found that relaxation-based interven-
tions showed little effectiveness in improving stress-
related immune disorders because of the insufficient
number of trials. Likewise, a higher number of relaxation
training sessions may be necessary to produce significant
changes in the immunological patterns.
In the elderly, cell marker expression is extremely im-
portant due to the decline of the immune system observed
in advancing age [18,60,61], with a decreased functional
capacity observed in studies of responses to mitogen
stimulation. The CD4/CD8 ratio is inverted [62] probably
due to the decline of the CD4 cells, although some au-
thors describe an increase in this population [63]. Others
authors describe a decrease in the number of cytotoxic T
cells, although clonal expansions of T CD8+ are also ob-
served [64] and may be due to proliferative responses to
tumoral or viral antigens [65]; the mechanisms leading to
these changes are still unclear [66].
Whether the increase or decrease of these immune pa-
rameters is a marker of clinical or health outcome is notclear. In this study, we describe the changes of B cells
(CD19+) population due to that it have been described
to decrease in patients with psychological alterations as
major depression [67], Alzheimer disease [68] or alcohol
dependence syndrome [69] which improved after psy-
chological therapy. This decreasing has also been found
in patients with breast cancer having a higher hopeful
attitude [70] or in patients that receive psychological
treatment before surgery in order to decrease their surgi-
cal anxiety [71]. However, B cells are increased in pa-
tients with acute schizophrenia [72] or university
students under stress periods [73]. In laboratory animals
(mouse) with experimental allergic or autoimmune en-
cephalomyelitis [74,75], as well as in multiple sclerosis
patients [76] has also been found the presence of
CD134+ cells localized in the active lesions. In children
with autism these activation markers decrease signifi-
cantly after in vitro lymphocyte stimulation [77]. There-
fore, the decrease of both cell populations observed in
our results after intervention concur with these previous
studies and it may be related to the positive effect and
improvements observed in these patients. The lack of
clarity in the relationship between changes in immune
parameters and health consequences might be in part
due to different subsets of B cells having different func-
tions and linkage to several systems [1]. However, previ-
ous studies [67-77] suggest that people who obtained
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nificant changes in the direction indicated in this study.
In conclusion, beneficial effects of relaxation techniques
on the functioning of the immune system in our study
could be inferred.
Our results could be initially explained on the basis of
the interconnection of sympathetic system, immune sys-
tem and psychological well-being, so that the effect of
the relaxation training on the sympathetic system is as-
sociated with a decline in psychological distress that per-
sists over time, albeit not significantly, and a modulation
of immune activity. In addition, our findings on the ef-
fect of the relaxation technique on the immune system
should be cautiously interpreted, given the following
considerations: (a) despite the homogeneity between the
two groups (treatment and waitlist control), from the
outset there were differences between them in the pro-
portion of segmented leukocytes and lymphocytes, and
(b) as shown in Table 4, both groups display significant
differences in CD71, CD97, and CD134 markers at the
end of treatment. In that sense, our conclusions must be
tentative. The immune system of elderly people who
show coexisting pathologies and are subjected to mul-
tiple pharmacological treatments could be faulty enough
to improve on its own.
The present study has limitations that need to be
taken into account when considering the study and its
findings. Although we have failed to observe consistent
immunological changes throughout the study, we did
obtain a relative increase in active circulating T lympho-
cytes. The fading of group differences at the three-month
follow-up is reasonable if we take into account that prac-
tice of the relaxation technique by the treatment group in
the course of those months was inconsistent. Moreover,
differences between the pre- and post-treatment assess-
ments in the control group, which obviously could not
be due to relaxation, could be attributed to a placebo
effect derived from the exhaustive medical testing, psy-
chological assessment, and greater professional support
received during the study. Another limitation of this
study is the reduced sample size; a larger sample could
facilitate the generalization of the results to the Spanish
population, as it would permit using more sophisticated
statistical methods which provide greater statistical
power and to achieve more definitive conclusions. Finally,
one aspect to consider, and that could have affected the
results of the treatment group, is the potential bias in
participant self-reports, given that they could have
responded based on what was expected of the treatment.
Nevertheless, we consider that this study provides inter-
esting data that clarify our understanding of the effects of
the relaxation response on psychological well-being and
the immune system in an elderly group residing in a
nursing home.Conclusions
Through this study we have found that the Benson’s relax-
ation technique or “tranquilization technique” used here
produced an improvement in the quality of life and a
modulation of the immune parameters in a group of eld-
erly people residing in a nursing home. Further studies
using the tranquilization technique in larger samples of
older people are needed to confirm the trends observed in
the present study.
Given that it is an easy and economical intervention, it
could be useful as a health resource in residential settings
where its daily practice could offer medium and long-term
benefits for the health and well-being of older adults.
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